ETON vs. CLSD, ACRS, ORMP, ANIX, MIST, ADAG, BYSI, PRPH, ONCY, and IOBT
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Clearside Biomedical (CLSD), Aclaris Therapeutics (ACRS), Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Adagene (ADAG), BeyondSpring (BYSI), ProPhase Labs (PRPH), Oncolytics Biotech (ONCY), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Clearside Biomedical (NASDAQ:CLSD) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Clearside Biomedical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
In the previous week, Clearside Biomedical had 8 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 19 mentions for Clearside Biomedical and 11 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.13 beat Clearside Biomedical's score of 0.11 indicating that Clearside Biomedical is being referred to more favorably in the media.
Eton Pharmaceuticals has a net margin of 2.66% compared to Eton Pharmaceuticals' net margin of -413.73%. Clearside Biomedical's return on equity of 5.65% beat Eton Pharmaceuticals' return on equity.
Eton Pharmaceuticals has higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Clearside Biomedical presently has a consensus price target of $4.50, indicating a potential upside of 265.85%. Eton Pharmaceuticals has a consensus price target of $9.00, indicating a potential upside of 153.52%. Given Eton Pharmaceuticals' higher possible upside, equities research analysts clearly believe Clearside Biomedical is more favorable than Eton Pharmaceuticals.
18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 9.8% of Clearside Biomedical shares are held by company insiders. Comparatively, 13.2% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Clearside Biomedical received 272 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 62.22% of users gave Eton Pharmaceuticals an outperform vote.
Summary
Eton Pharmaceuticals beats Clearside Biomedical on 9 of the 17 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
